# Pilot HCV Direct Acting Antiviral Therapy and Metabolism

> **NCT02734173** · PHASE4 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 24 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** ABT450r-ABT267-ABT333 +/- Ribavirin

## Key facts

- **NCT ID:** NCT02734173
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2017-02
- **Final completion:** 2017-05-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02734173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02734173, "Pilot HCV Direct Acting Antiviral Therapy and Metabolism". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02734173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*